| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
507 |
| issn |
1743-4254
1743-4262 |
| issueIdentifier |
9 |
| pageRange |
506-507 |
| publicationName |
Nature clinical practice. Oncology |
| startingPage |
506 |
| bibliographicCitation |
Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol. 2008 Sep;5(9):506–7. doi: 10.1038/ncponc1201. PMID: 18648352. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59299312a9cb5addfb36a42aa0000abc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ba07d1c4fc8b81a692d36538ccb9873 |
| date |
2008-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/18648352
https://doi.org/10.1038/ncponc1201 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1743-4254
https://portal.issn.org/resource/ISSN/1743-4262
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32524 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/ |
| title |
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4212 |